Converting IV Fentanyl Infusion to Oral Morphine

Introduction to Conversion

The National Comprehensive Cancer Network recommends converting IV fentanyl infusion to oral morphine using a two-step calculation, first converting IV fentanyl to IV morphine using a 100:1 ratio, then converting IV morphine to oral morphine using a 1:3 ratio, with a 25-50% dose reduction to account for incomplete cross-tolerance 1, 2, 3

The conversion ratio of 100:1 (100 mcg IV fentanyl = 10 mg IV morphine) can be used to convert IV fentanyl to IV morphine, and then the conversion ratio of 1:3 (1 mg IV morphine = 3 mg oral morphine) can be used to convert IV morphine to oral morphine 1, 2, 3
A dose reduction of 25-50% should be applied to the calculated oral morphine dose to account for incomplete cross-tolerance, as recommended by the National Comprehensive Cancer Network 1, 2

Clinical judgment must be used when converting IV fentanyl to oral morphine, as these conversion ratios are approximate due to patient variability, and the National Comprehensive Cancer Network recommends monitoring closely for signs of inadequate pain control or opioid toxicity during the first 24-48 hours 1, 2, 3
A safety-first approach should be used, starting with a lower dose (using the 50% reduction) and titrating upward based on response, as recommended by the National Comprehensive Cancer Network 1, 2

The National Comprehensive Cancer Network establishes that the equianalgesic conversion ratio for IV fentanyl to IV morphine is 100:1, meaning 100mcg IV fentanyl is equivalent to 10mg IV morphine 4
For 1800mcg IV fentanyl, the equivalent dose is 180mg IV morphine, calculated using the 1:100 conversion ratio 4
This 1:100 ratio applies ONLY to IV fentanyl compared with IV morphine, and does not apply to transdermal fentanyl, which uses entirely different conversion calculations 4

When rotating opioids, if pain was well-controlled on the original opioid, reduce the calculated equianalgesic dose by 25-50% to account for incomplete cross-tolerance, as recommended by the National Comprehensive Cancer Network 4, 5
If pain was poorly controlled, you may use 100% of the equianalgesic dose or increase by 25%, according to the National Comprehensive Cancer Network guidelines 4
Always provide breakthrough medication during opioid rotation, typically 10-20% of the total 24-hour dose as short-acting opioid, as suggested by clinical guidelines 5, 6

The National Comprehensive Cancer Network recommends dividing the total daily IV morphine dose by 6 for every-4-hour dosing with immediate-release oral morphine, and by 2 for every-12-hour dosing with extended-release formulations 7
For patients with well-controlled pain, the calculated oral morphine dose should be reduced by 25-50% to account for incomplete cross-tolerance, and the National Comprehensive Cancer Network suggests starting with the lower dose (50% reduction) and titrating upward based on response 7

The National Comprehensive Cancer Network advises against using morphine entirely if creatinine clearance is below 30 mL/min due to accumulation of toxic metabolites, and instead recommends using alternative opioids such as fentanyl or hydromorphone 7
If morphine must be used despite renal impairment, the National Comprehensive Cancer Network recommends starting with 25-50% of the calculated dose and monitoring closely for myoclonus, confusion, and respiratory depression 7

The National Comprehensive Cancer Network suggests monitoring patients closely for the first 24-48 hours for signs of inadequate pain control or opioid toxicity, and reassessing pain and side effects every 4-6 hours initially 7
If a patient requires more than 3-4 breakthrough doses per day, the National Comprehensive Cancer Network recommends increasing the scheduled baseline dose by 25-50% 7

The National Comprehensive Cancer Network warns against using the transdermal fentanyl conversion ratio when converting from IV fentanyl, and against forgetting the dose reduction for incomplete cross-tolerance 7
The National Comprehensive Cancer Network also advises against prescribing morphine in severe renal impairment (CrCl <30 mL/min) due to toxic metabolite accumulation, and against using mixed agonist-antagonist opioids during or after this conversion 7